Pfizer Inc. Stock
€22.44
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.000% | 0.831% | 2.959% | 6.275% | 5.451% | -38.772% | -31.450% |
| BioMarin Pharmaceutical Inc. | -1.660% | -5.323% | 6.480% | -2.424% | -6.699% | -46.022% | -30.914% |
| Biogen Inc. | -0.070% | -2.342% | 1.482% | 48.571% | 12.432% | -38.059% | -48.335% |
| Zoetis Inc. A | 0.380% | -4.017% | 6.948% | -51.961% | -36.345% | -56.234% | -55.450% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
If it weren't for question marks about its future growth, Pfizer (NYSE: PFE) stock would undoubtedly be trading at a much higher price. Sales were down last year, and the stock has been floundering,
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug market, to be sure. Lilly sold $13.5 billion worth of GLP-1-based Zepbound
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal Pharmaceuticals says it is entering a stronger growth phase, helped by unexpectedly solid
